biostudies-literaturePole JDNCI NIH HHS540-545https://www.ebi.ac.uk/biostudies/studies/S-EPMC5318976biostudies-literatureUnknown116(4)<h4>Background</h4>Objectives were to describe the proportion of deaths due to treatment-related mortality (TRM) and to identify risk factors and probable causes of TRM among paediatric cancer deaths in a population-based cohort.<h4>Methods</h4>We included children with cancer ⩽18 years diagnosed and treated in Ontario who died between January 2003 and December 2012. Deaths were identified using a provincial registry, the Pediatric Oncology Group of Ontario Networked Information System. Probable causes of TRM were described.<h4>Results</h4>Among the 964 deaths identified, 821 were included. The median age at diagnosis was 6.6 years (range 0-18.8) and 51.8% had at least one relapse. Of the deaths examined, TRM occurred in 217/821 (26.4%) while 604/821 (73.6%) were due to progressive cancer.British journal of cancerEvaluation of treatment-related mortality among paediatric cancer deaths: a population based analysis.PMC5318976UG1 CA189955Sung LJohnston DLSilva MAlexander SGibson PLazor TPortwine CEthier MCPole JDfalseEvaluation of treatment-related mortality among paediatric cancer deaths: a population based analysis.<h4>Background</h4>Objectives were to describe the proportion of deaths due to treatment-related mortality (TRM) and to identify risk factors and probable causes of TRM among paediatric cancer deaths in a population-based cohort.<h4>Methods</h4>We included children with cancer ⩽18 years diagnosed and treated in Ontario who died between January 2003 and December 2012. Deaths were identified using a provincial registry, the Pediatric Oncology Group of Ontario Networked Information System. Probable causes of TRM were described.<h4>Results</h4>Among the 964 deaths identified, 821 were included. The median age at diagnosis was 6.6 years (range 0-18.8) and 51.8% had at least one relapse. Of the deaths examined, TRM occurred in 217/821 (26.4%) while 604/821 (73.6%) were due to progressive cancer.2017-01-01T00:00:00Z2017 Feb2025-04-22T19:20:01.821Z2019-03-26T23:01:50ZS-EPMC53189762809539910.1038/bjc.2016.443